National Clinical Trials Network Research at the University of Wisconsin
威斯康星大学国家临床试验网络研究
基本信息
- 批准号:10590665
- 负责人:
- 金额:$ 63.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-03-06 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:American College of Radiology Imaging NetworkAmerican College of Surgeons Oncology GroupCancer BurdenCancer CenterCancer PatientClinicalClinical ResearchClinical SciencesClinical TrialsCollaborationsCooperative Group ProgramDataDevelopmentEastern Cooperative Oncology GroupEnsureFacultyGenomicsGoalsGrantGynecologic OncologyGynecologic Oncology GroupImageImaging TechniquesInfrastructureInstitutionLeadershipMalignant NeoplasmsMedical OncologyMissionModernizationNCI Center for Cancer ResearchNational Clinical Trials NetworkOncologyPhasePhase II/III Clinical TrialPopulationPopulation HeterogeneityPreventionPrincipal InvestigatorProtocols documentationRadiation OncologyRadiation Therapy Oncology GroupResearchResearch InfrastructureResearch PersonnelResourcesStrategic PlanningStructureSurgical OncologyTherapeuticTranslational ResearchUnderserved PopulationUniversitiesUniversity of Wisconsin Comprehensive Cancer CenterWisconsincancer clinical trialcancer educationcancer therapydata managementdesignexperienceinnovationinterdisciplinary approachinterestmultidisciplinarynext generationnovelprogramstreatment trial
项目摘要
Project Summary/Abstract
The University of Wisconsin Carbone Cancer Center (UWCCC), its leadership, and its faculty are driven by a
mission to defeat cancer through rapid application of groundbreaking research in cancer education, prevention
and treatment. Embedded in the UWCCC's strategic plan are tactics for expanding a modern research platform
inclusive of a comprehensive clinical research program with exemplary data management and clinical trial
prioritization as well as scientific oversight and leadership. The UWCCC NCTN LAPs multi-disciplinary team
remains an integral component of this strategic initiative and collaborates with key faculty to support innovative
translational research for next generation clinical trials within the NCI's National Clinical Trials Network.
Since 1974, UWCCC faculty have functioned as leaders in the development of the NCI cancer cooperative group
program; first within ECOG and then with RTOG, ACOSOG and GOG in the early 2000s. As the NCI and its
NCTN transitioned to a centralized infrastructure in 2014, the UWCCC designed a LAPS team of collaborative
principal investigators by combining the existing broad scientific leadership from three of the primary cooperative
groups (ECOG/ACRIN, NRG and ALLIANCE). This multi-disciplinary approach with leaders from Surgical,
Medical, Radiation and Gynecologic Oncology, facilitated an innovative governance structure to provide
leadership and oversight in prioritization of Phase II/III clinical trials, timely trial activation and robust accrual as
well as the development of junior faculty interested in oncologic clinical research. In the four years since our last
grant submission, the UWCCC LAPS team has provided support for the important genomically-directed clinical
trials as well as those with a focus on advanced imaging, while strengthening our Cancer Center's infrastructure.
This UG1 application seeks support for continuing the NCTN activities within the UWCCC. This partnership
remains an important mechanism for providing a diverse population of cancer patients with novel treatment
approaches, as well as a means for providing resources and support for existing and new leaders within the
NCTN to bring innovative translational projects to Phase II/III clinical trials.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lisa M Barroilhet其他文献
Lisa M Barroilhet的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lisa M Barroilhet', 18)}}的其他基金
Repurposing Atovaquone for Preventing Ovarian Cancer: An Example of Successful Inhibition of Oxidative Phosphorylation
重新利用阿托伐醌预防卵巢癌:成功抑制氧化磷酸化的一个例子
- 批准号:
10524134 - 财政年份:2020
- 资助金额:
$ 63.42万 - 项目类别:
Repurposing Atovaquone for Preventing Ovarian Cancer: An Example of Successful Inhibition of Oxidative Phosphorylation
重新利用阿托伐醌预防卵巢癌:成功抑制氧化磷酸化的一个例子
- 批准号:
10813900 - 财政年份:2020
- 资助金额:
$ 63.42万 - 项目类别:
Repurposing Atovaquone for Preventing Ovarian Cancer: An Example of Successful Inhibition of Oxidative Phosphorylation
重新利用阿托伐醌预防卵巢癌:成功抑制氧化磷酸化的一个例子
- 批准号:
10162548 - 财政年份:2020
- 资助金额:
$ 63.42万 - 项目类别:
NCI Diversity Supplement- Mayra Alejandra Betancourt Ponce
NCI 多样性补充 - Mayra Alejandra Betancourt Ponce
- 批准号:
10381309 - 财政年份:2020
- 资助金额:
$ 63.42万 - 项目类别:
Repurposing Atovaquone for Preventing Ovarian Cancer: An Example of Successful Inhibition of Oxidative Phosphorylation
重新利用阿托伐醌预防卵巢癌:成功抑制氧化磷酸化的一个例子
- 批准号:
10414919 - 财政年份:2020
- 资助金额:
$ 63.42万 - 项目类别:
The MW Cancer Prevention Clinical Trials Network
MW 癌症预防临床试验网络
- 批准号:
10704531 - 财政年份:2020
- 资助金额:
$ 63.42万 - 项目类别:
Repurposing Atovaquone for Preventing Ovarian Cancer: An Example of Successful Inhibition of Oxidative Phosphorylation
重新利用阿托伐醌预防卵巢癌:成功抑制氧化磷酸化的一个例子
- 批准号:
10658885 - 财政年份:2020
- 资助金额:
$ 63.42万 - 项目类别:
National Clinical Trials Network Research at the University of Wisconsin
威斯康星大学国家临床试验网络研究
- 批准号:
10112744 - 财政年份:2019
- 资助金额:
$ 63.42万 - 项目类别:
National Clinical Trials Network Research at the University of Wisconsin
威斯康星大学国家临床试验网络研究
- 批准号:
9888349 - 财政年份:2019
- 资助金额:
$ 63.42万 - 项目类别:
National Clinical Trials Network Research at the University of Wisconsin
威斯康星大学国家临床试验网络研究
- 批准号:
10358646 - 财政年份:2019
- 资助金额:
$ 63.42万 - 项目类别:














{{item.name}}会员




